I would be very careful here. It is by no means a lock. It looks like we have a long tail, but what is its composition? Why are these patients alive so long? What is the MOA? What about the primary and secondary endpoints? Have they been met? Are they stat significant? If not, would the FDA grant approvals based only on the long tail? Medical device approvals are different than drug approvals. If the results are mixed but maybe approvable, how long would approval take? With mixed but good, not stellar overall results, where do the pps go? The science may be good, but NWBO as an investment???
I am very cautiously optimistic based on the blended data and LL SNO update but this is still very high risk. NWBO's lack of transparency is also very troubling. It is encouraging that they may go to data lock sooner rather than later but exactly when? The multi-month process prior to unblinding is also concerning. Knowing NWBO, this could drag on until late 2019 at the earliest. And all the while silence and perhaps additional toxic financings.
News about business transactions which were planned to be announced within several weeks after ASCO, 2018 have not been announced going on 6 months!? I can almost guarantee that there are no licensing, JV, BO or other negotiations going on without unblinding. As I said before, LP is going for broke. The implication is that unveiling is to occur relatively soon. A buyer, partner, licensee would be very wary if now, LP would sell out cheaply---wouldn't pass the smell test. No one will pay close to LP's asking price for a pig in the polk. So, what's left? Sawston? If so, what is taking so long? A bidding competition as some have suggested on this board? I doubt it. The delay is very concerning and LP had to go to yet another toxic financing, albeit small, to tide her over. Is it a bridge to nowhere?
Many questions without many answers and the "stay tuned" mantra. My view is that the science is promising. NWBO management? Different story. Overall, NWBO is very high risk. JMHO.
